GDM - Screening methods, Glucose metabolism and Management 30 marks question in PG obs and gynce
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Searching Images
gestational diabetes mellitus screening glucose tolerance test GDM diagnosis
Reading File
Loading Image
I now have comprehensive material to write a thorough 30-mark PG answer. Let me compile the complete answer.
Gestational Diabetes Mellitus (GDM): Screening, Glucose Metabolism & Management
A Complete 30-Mark PG Answer
DEFINITION
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy. It occurs in approximately 8% of all pregnancies and is one of the most common metabolic complications in obstetric practice. (Harrison's Principles of Internal Medicine, 22E)
PART I: GLUCOSE METABOLISM IN PREGNANCY
Understanding GDM requires appreciating the normal physiological changes in glucose metabolism during pregnancy.
A. Normal Glucose Metabolism in Pregnancy
Pregnancy induces a biphasic metabolic pattern:
Early Pregnancy (1st Trimester):
- Increased insulin sensitivity transiently at 12-14 weeks
- Enhanced peripheral glucose uptake
- Decreased fasting glucose and increased hepatic glycogen synthesis
- Rising estrogen and progesterone promote beta-cell hyperplasia
- Net result: mild hypoglycemia in fasting state - "accelerated starvation"
Late Pregnancy (2nd & 3rd Trimester):
- Progressive insulin resistance - glucose infusion rate falls significantly (see Fig. 59.4 - Creasy & Resnik)
- Insulin secretory response increases approximately 3-fold compared to pregravid state (2nd and 3rd phase insulin response)
- Despite increased secretion, insulin sensitivity falls markedly by 34-36 weeks
- The net effect is maintenance of normoglycemia in healthy women through compensatory hyperinsulinemia
Figure: Longitudinal changes in insulin sensitivity (glucose infusion rate) from pregravid state through early (12-14 weeks) and late (34-36 weeks) pregnancy - Creasy & Resnik
B. The Fetoplacental Unit and Glucose Handling
- The fetoplacental unit shunts glucose and amino acids to the fetus while the mother preferentially uses ketones and triglycerides
- Fetal glucose uptake causes maternal accelerated ketosis during fasting - lower glucose and higher hydroxybutyrate
- Placental hormones responsible for insulin resistance include:
- Human placental lactogen (hPL)
- Placental growth hormone variant
- Progesterone and cortisol
- TNF-alpha and leptin
- hPL peaks progressively and is the dominant anti-insulin factor
C. Mechanisms of Gestational Insulin Resistance (GDM-Specific)
(Creasy & Resnik's MFM, p.1429)
In women who develop GDM, specific metabolic defects are present:
- Increased basal endogenous glucose production - similar to type 2 DM
- Decreased insulin-mediated glucose uptake - insulin infusion assays show insulin's ability to suppress endogenous glucose production is reduced (~80% vs 95% in normal women)
- Impaired first-phase insulin secretion - failure of beta-cell compensation is the key defect
- Decreased insulin sensitivity - persists antepartum and postpartum; women with GDM have significantly lower insulin sensitivity than matched controls even after delivery
- Across the body weight spectrum, fasting insulin concentrations (especially in late gestation) are greater than in normal glucose-tolerant women - reflecting compensatory hyperinsulinemia
Key concept: GDM represents a failure of the beta-cell to fully compensate for the physiological insulin resistance of late pregnancy. Women with GDM carry a pre-existing beta-cell dysfunction or pre-diabetes that is unmasked by pregnancy.
PART II: SCREENING FOR GDM
A. When to Screen
- Universal screening at 24-28 weeks of gestation (recommended by ACOG, ADA, USPSTF - Grade B recommendation)
- High-risk screening at the first prenatal visit for women with risk factors:
- BMI ≥25 kg/m² (or ≥23 kg/m² in Asian populations)
- Prior history of GDM
- Prior macrosomic infant (>4 kg)
- First-degree relative with type 2 DM
- Polycystic ovarian syndrome
- Previous unexplained stillbirth
- Glycosuria on two occasions
- Ethnicity: South Asian, Hispanic, African American, Pacific Islander
B. Screening Strategies
There are two internationally recognized strategies:
ADA Screening Table: 1-step vs 2-step GDM diagnosis criteria
Strategy 1: One-Step (IADPSG/WHO 2013)
Adopted by IADPSG (International Association of Diabetes and Pregnancy Study Groups) and WHO. Used widely in India (DIPSI is a variant).
Test: 75-g OGTT (fasting), at 24-28 weeks
Diagnosis if ANY ONE value is met or exceeded:
| Timepoint | Threshold |
|---|---|
| Fasting | ≥92 mg/dL (5.1 mmol/L) |
| 1 hour | ≥180 mg/dL (10.0 mmol/L) |
| 2 hours | ≥153 mg/dL (8.5 mmol/L) |
- Based on data from the HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes) - a landmark study of >25,000 pregnant women showing continuous linear relationship between maternal glucose and adverse outcomes
- Increased sensitivity, detects more GDM, but increases treatment burden and resource use
Strategy 2: Two-Step (ACOG / USA standard)
Step 1 - Screening Test (non-fasting):
- 50-g Glucose Challenge Test (GCT) at 24-28 weeks
- Single plasma glucose at 1 hour
- Positive screen: plasma glucose ≥130 mg/dL (or ≥135 or ≥140 mg/dL per local protocol)
- If positive → proceed to Step 2
Step 2 - Diagnostic Test (fasting):
- 100-g OGTT, with plasma glucose fasting and at 1h, 2h, 3h
Carpenter-Coustan Criteria (ACOG recommended):
| Timepoint | Threshold |
|---|---|
| Fasting | ≥95 mg/dL (5.3 mmol/L) |
| 1 hour | ≥180 mg/dL (10.0 mmol/L) |
| 2 hours | ≥155 mg/dL (8.6 mmol/L) |
| 3 hours | ≥140 mg/dL (7.8 mmol/L) |
Diagnosis requires 2 or more elevated values (ACOG allows 1 elevated value in some guidelines)
NDDG Criteria (older, less used):
- Fasting: 105 mg/dL | 1h: 190 | 2h: 165 | 3h: 145 mg/dL
C. DIPSI (Diabetes in Pregnancy Study Group India) Criteria
A practical, single-step, non-fasting test used widely in India - suitable for resource-limited settings:
- 75-g oral glucose regardless of fasting state
- Single 2-hour plasma glucose
- GDM: ≥140 mg/dL
- Impaired GDM: 120-139 mg/dL
D. Other Screening Methods
| Test | Notes |
|---|---|
| Fasting plasma glucose | ≥92 mg/dL = GDM per IADPSG; cheap, simple |
| HbA1c | Not reliable in pregnancy - red cell turnover is increased causing falsely low values; used at booking to detect pre-existing DM (≥6.5% = overt DM) |
| Random blood glucose | ≥200 mg/dL + symptoms = overt DM |
| Urine glucose (glycosuria) | Poor sensitivity and specificity; renal threshold lowers in pregnancy; not recommended as sole screening tool |
| Glycated proteins (fructosamine) | Research use |
E. Key Clinical Points for Screening
- GCT can be done non-fasting (50-g)
- OGTT must be done fasting (overnight fast ≥8 hours)
- Patient must have unrestricted carbohydrate diet for 3 days prior to OGTT
- Patient should remain seated during OGTT; smoking prohibited
- Venous plasma glucose is the standard (fingerstick glucometers are NOT acceptable for diagnosis)
PART III: MANAGEMENT OF GDM
Management follows a stepwise approach: Dietary modification → Physical activity → Medical therapy (insulin/oral agents) → Obstetric surveillance.
(Creasy & Resnik's MFM; Harrison's 22E)
A. Target Glucose Values in GDM
| Timepoint | Target |
|---|---|
| Fasting / pre-meal | 65-95 mg/dL (ADA: <95 mg/dL) |
| 1-hour postprandial | <140 mg/dL |
| 2-hour postprandial | <120 mg/dL |
| Mean blood glucose | <100 mg/dL |
HbA1c monitoring is of minimal utility in pregnancy due to increased red cell turnover causing falsely low values. Blood glucose self-monitoring (SMBG) is the standard.
B. Non-Pharmacological Management
1. Medical Nutrition Therapy (MNT)
- Cornerstone of initial GDM management
- Caloric intake tailored to pre-pregnancy BMI:
- Normal BMI: 30 kcal/kg/day
- Overweight: 25 kcal/kg/day
- Obese: 15-20 kcal/kg/day (minimum 1800 kcal/day)
- Carbohydrate restriction to 35-45% of total calories, spread over 3 meals + 2-3 snacks
- Complex carbs with low glycaemic index preferred
- Adequate protein (20%) and fat (35-40%)
- Approximately 50% of women achieve adequate glucose control with diet alone (McFarland et al.)
2. Physical Activity
- Moderate aerobic exercise for 30 min, 3-5 times/week
- Postprandial walking (15-30 min) significantly reduces postprandial glucose
- Resistance training also beneficial
- Reduces insulin resistance and aids gestational weight management
- Contraindicated in placenta previa, preterm labor risk, severe hypertension
Important timing point: Allow only 1-2 weeks of dietary management before initiating medical therapy. Waiting longer misses the critical window of 28-34 weeks (period of accelerated fetal fat accretion). By 4 weeks of dietary therapy, only an additional 10% of patients achieve control (McFarland et al.).
C. Pharmacological Management
1. Insulin - PREFERRED First-Line Agent
Insulin is the gold standard for GDM treatment due to:
- Does not cross the placenta (no direct fetal effect)
- Proven safety and efficacy
- Lower treatment failure rates than oral agents
- Recommended by both ACOG and ADA as preferred therapy
Key landmark trials:
- ACHOIS Trial (Crowther et al.) - 1000 women; insulin-treated GDM had significantly lower serious perinatal complications (1% vs 4%) and lower leptin concentration (indicating less fetal fat mass)
- Landon et al. multicenter RCT - Treatment of mild GDM with insulin significantly reduced LGA (7.1% vs 14.5%), birth weight >4000g (5.9% vs 14.3%), shoulder dystocia (1.5% vs 4.0%), CS rates (26.9% vs 33.8%), and preeclampsia
Types of Insulin in Pregnancy (Creasy & Resnik, Table 59.12):
| Insulin Type | Onset | Peak | Duration | Notes |
|---|---|---|---|---|
| Regular insulin | 30-60 min | 2-4h | 6-8h | Safe; standard bolus |
| Lispro (Humalog) | 5-15 min | 30-90 min | 3-5h | Rapid-acting; preferred bolus |
| Aspart (Novolog) | 5-15 min | 30-90 min | 3-5h | Rapid-acting; safe in pregnancy |
| NPH | 1-2h | 4-8h | 12-16h | Traditional basal; cheap |
| Detemir (Levemir) | 1-2h | Flat | 18-24h | Long-acting; safe in pregnancy |
| Glargine (Lantus) | 1-2h | Flat | 20-24h | Data supports safety; some concerns |
| Degludec (Tresiba) | Slow | Flat | >42h | Limited pregnancy data |
Insulin Regimens:
- Typical starting dose for GDM: 0.7-0.8 units/kg/day (1st trimester) → 0.8-1.0 units/kg (2nd trimester) → 0.9-1.2 units/kg (3rd trimester)
- Combination regimen: Basal insulin (NPH or detemir) + rapid-acting bolus at meals
- Insulin pump (CSII) may be used in selected patients with pregestational DM
- Doses require weekly or more frequent adjustment as pregnancy progresses
Fasting hyperglycemia → treat with bedtime NPH or long-acting insulin
Postprandial hyperglycemia → treat with rapid-acting insulin before meals
2. Metformin
- Not recommended as first-line by ACOG or ADA for GDM
- Mechanism: Reduces hepatic glucose output, improves insulin sensitivity
- Key concern: Significant transplacental passage - metformin crosses to fetal compartment; inadequate long-term offspring safety data
- Studies show higher adiposity measurements in metformin-exposed children in utero
- MiTy Trial (Feig et al.) - metformin added to insulin in T2DM pregnancy led to lower HbA1c, lower insulin requirements, less weight gain, fewer CS deliveries, fewer LGA infants - but more SGA infants and lower birth weight
- Equivalent to insulin in short-term efficacy for GDM when insulin is not feasible
- Acceptable alternative when patient declines or cannot reliably administer insulin
- Dose: 500 mg once daily, titrate to max 2500 mg/day in divided doses
3. Glyburide (Glibenclamide)
- Currently NOT recommended by ACOG or ADA due to inferior outcomes compared to insulin and metformin
- Crosses placenta; associated with neonatal hypoglycemia
- Higher rates of macrosomia and NICU admissions compared to insulin
- If used: 2.5-5 mg twice daily (given 2 hours before meals), maximum 20 mg/day
D. Antepartum Fetal Surveillance
| Assessment | Frequency |
|---|---|
| Ultrasound for growth | Every 4 weeks from 28 weeks |
| Fetal weight estimation | 32-36 weeks to detect macrosomia |
| Biophysical profile / NST | Weekly from 36 weeks (or 32 weeks if poorly controlled) |
| Amniotic fluid index | For polyhydramnios (sign of poor glycemic control) |
| Umbilical artery Doppler | If IUGR or suspected |
Ultrasound identification of a large for gestational age (LGA) fetus or polyhydramnios are indicators of suboptimal glycemic control.
E. Continuous Glucose Monitoring (CGM)
- CONCEPTT Trial (T1DM in pregnancy) - CGM showed mild improvement in HbA1c, reduced LGA births, shorter NICU stay, and reduced neonatal hypoglycemia
- Target ranges (TIR) for T1DM pregnancy:
- Target range 63-140 mg/dL: goal >70% time in range
- Time below range (<63 mg/dL): goal <4%
- Time above range (>140 mg/dL): goal <25%
- Role in GDM is growing but evidence base developing
F. Obstetric Management - Timing and Mode of Delivery
| Scenario | Management |
|---|---|
| Diet-controlled GDM, no complications | Allow labor up to 40-41 weeks; ACOG suggests delivery by 40+6 |
| Insulin-treated GDM, well controlled | Induce at 39-40 weeks |
| Poorly controlled GDM | Deliver at 37-38 weeks |
| Estimated fetal weight ≥4500 g | Elective CS to prevent shoulder dystocia |
| Macrosomia (EFW ≥4000 g with suboptimal control) | Consider early induction |
Intrapartum management:
- Tight glucose control during labor (target 80-110 mg/dL)
- IV insulin infusion if needed during active labor
- Monitor fetal heart rate continuously
G. Complications of GDM
Maternal:
- Preeclampsia (2-4x increased risk)
- Operative delivery
- Risk of type 2 DM (7-10x increased risk; 10% develop T2DM within 5 years of delivery)
- Recurrence in subsequent pregnancies (30-50%)
Fetal/Neonatal:
- Macrosomia and LGA
- Shoulder dystocia and birth trauma (brachial plexus injury)
- Neonatal hypoglycemia (fetal hyperinsulinemia)
- Polycythemia
- Respiratory distress syndrome
- Hyperbilirubinemia
- Long-term childhood obesity and metabolic syndrome
H. Postpartum Management
- All GDM patients should have a 75-g 2-hour OGTT at 4-12 weeks postpartum to screen for persistent diabetes or impaired glucose tolerance
- If normal, retest every 1-3 years lifelong
- Metformin reduces the risk of T2DM in high-risk GDM patients postpartum
- Breastfeeding encouraged - reduces maternal insulin resistance
- Exercise and weight loss reduce long-term diabetes risk
- Lifestyle modification: most effective intervention to prevent progression to T2DM
SUMMARY TABLE
| Aspect | Key Points |
|---|---|
| Prevalence | ~8% of pregnancies |
| Pathophysiology | Failure of beta-cell compensation for physiological insulin resistance; placental anti-insulin hormones (hPL, cortisol) |
| Screening timing | 24-28 weeks universal; first visit for high-risk |
| One-step (IADPSG) | 75g OGTT: F ≥92, 1h ≥180, 2h ≥153 mg/dL (any one) |
| Two-step (ACOG) | 50g GCT → if ≥130: 100g OGTT (C-C criteria: F 95, 1h 180, 2h 155, 3h 140) |
| DIPSI (India) | 75g non-fasting, 2h value ≥140 mg/dL |
| Glucose targets | Fasting <95, 1h postprandial <140, 2h <120 mg/dL |
| First-line Rx | Diet + exercise → Insulin (if targets not met) |
| Insulin dose | 0.7-1.2 units/kg/day (increases each trimester) |
| Metformin | Acceptable alternative, not first-line; crosses placenta |
| Glyburide | Not recommended (ACOG, ADA 2024) |
| Delivery | Well-controlled: 39-40 weeks; CS if EFW ≥4500g |
| Postpartum | 75g OGTT at 4-12 weeks; lifelong annual screening |
Sources: Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (9780323828499); Harrison's Principles of Internal Medicine 22E (9781265977061); ADA GDM Screening Table (ADA Standards of Care)
This is a shared conversation. Sign in to Orris to start your own chat.